Group Profile

CEO Speech

Going back from the establishment of The Celconta Group to its development and growth, can not help but feel a lot of emotion.

From a small company with only a few people to established enterprises; from the Nothing to building an advanced R&D platform, developing core technologies with independent intellectual property rights, winning various awards and certifications. All this, The Celconta Group only took three years!

Learn more

Group Profile

The Celconta Group encompasses multiple biotech companies that specialize in cell storage, research and development, production, and commercialization.With "precision medicine" as the core, the Group has built industrial clusters such as cell cryopreservation, cell medicine and development, and regenerative medicine, etc. Its business covers the upper, middle and lower reaches of the cell industry, establishing an industry with a full production chain. The group owns 2 "national high-tech enterprises" and 18 subsidiaries.

With strong scientific research strength, the group has developed a number of technology platforms with independent intellectual property rights, and through the identification of "Gazelle Enterprise", it has been approved to build "Songshan Lake Comprehensive Cell Bank", "Songshan Lake Regional Cell Preparation Center" and "Dongguan Cell Therapy Engineering Technology Research Center". Its Dongguan Life Bank is a leading cell storage center in South China, and the public service platform for cell quality testing has been recognized by CNAS. The preparation of UCMSC(umbilical cord mesenchymal stem cell) passed the quality review inspection of National Institutes for Food and Drug Control, and CAR-T cell preparations are being carried out clinical trials of solid tumors in many Grade-A tertiary hospitals.

We implement the 2027 "Ten, Hundred, Thousand" development strategy, that is, achieve "cumulative revenue reaching 1 billion, group valuation reaching 10 billion, and number of employees reaching 1,000" by 2027, and strive to become a leading enterprise in the field of cell and gene therapy (CGT) in China.

170

A total of more than 170 patent applications
500

Nearly 500 employees
10000

With more than 10,000
square meters of GMP-like laboratory

Company Culture

Mission

Let the sick live with dignity and let the healthy live longer

Mission
Vision

Dedicated to becoming a leader in the field of cell therapy in China

Vision
Sense of worth

Win by mutual benefit and be kind to others

Sense of worth
Management Philosophy

Strictest Standard,Greatest Effort

Management Philosophy
Business Philosophy

Coordinated development and win-win cooperation

Business Philosophy

Strategic Layout

The Celconta Group has formulated a "1+4+30" development strategy, and strives to achieve "1 headquarters, 4 development directions and 30 holding subsidiaries" by 2025. Strategic layout, build a 4-hour channel network and actively promote the commercial application of related products/technologies.

Learn more

Qualification Honor

Development History

2024

In January

Celconta Group has been selected as a pilot enterprise for the "Double Multiplication" program.
In January

Celconta's subsidiary, Zailijian Biotech, has been certified as a "National High-Tech Enterprise".
In March

Celconta Group has been featured on the "Future Creation Star List".
In March

Mr. Xie Haitao, Chairman of Celconta Group, was featured on the "Outstanding Innovators List".
In July

Celconta Life's latest research findings on CAR-T therapy were published in Molecular Therapy.
In July

The independently developed serum-free culture medium for immune cells has successfully received registration with the FDA's Drug Master File (DMF).
In September

Celconta Group has been awarded the title of "Dongguan Science Education Base".

2023

In January

Recognized by Guangdong Province as a "Specialized, Refined, Differentiated, and Innovative" Small and Medium-Sized Enterprise.
In May

Celconta Life has received pre-A round investment from Lianjing Investment Group.
In May

Celconta Group has formed a strategic partnership with Thailand's Acquest Company in cell therapy, marking the start of its international development strategy.
In May

Celconta Group has collaborated with Guangdong Medical University to establish a "Graduate Student Joint Training Base".
In May

Celconta Group was recognized as one of the "Top 10 Most Promising Companies" in the Greater Bay Area's 2022 Sci-Tech Innovation Enterprise Growth Ranking.
In June

Celconta Group has been selected into the list of pilot enterprises of Dongguan's "Multiplication Plan".
In June

Celconta Group is ranked among the "Top 10 Most Promising Innovative Therapy Companies" on the Huayi Medical List.
In September

The China Society For Public Economics of the Party School of the CPC Central Committee (National Academy of Governance) recently conducted a research visit to Celconta Group.
In October

Professor Ning Ke's team’s gene therapy drug development project won the top honor, the "Top 50 Pioneer Award", at the 2023 Songhu Cup Innovation and Entrepreneurship Competition.
In November

The inaugural stem cell clinical research project has been officially launched at the First Affiliated Hospital of Wannan Medical College.

2022

In January

it became an Enterprise above designated Size.
In June

Lianjing Investment Group completed the pre-A round of financing.
In July

The Dongguan Life Bank was opened.
In August

approved by CNAS.
In August

through the municipal engineering and technology research center identified.
In September

through the Gazelle Enterprise identification.
In September

hostsd the 2022 Greater Bay Area Cell Industry Innovation and Development Forum.
In November

through the innovative small and medium-sized enterprises identified.
In December

the preparation of UCMSC(umbilical cord mesenchymal stem cell) passed the quality review inspection of National Institutes for Food and Drug Control.
In December

First Conder Life through the innovative small and medium-sized Enterprises identified.
In December

First Conder Life through the national high-tech Enterprise identification.

2021

On January 19th

First Condor Biotechnology passed the ISO9001 quality management system certification.
On April 6th

First Condor Biotechnology passed the intellectual property management system certification.
On May 7th

the media "Southern+" under the Southern Press Group published a news report "Focus on Innovation and Entrepreneurship | Songshan Lake Creation Competition Award-Winning Enterprises Deepen Cell Therapy, Focusing on the "Unique Skill", reporting on First Condor Biotechnology.
On June 8th

with the approval of the government department, First Condor Biotechnology was approved to build the "Songshan Lake (First Condor) Regional Cell Preparation Center and Comprehensive Cell Bank".
On June 12th

the opening ceremony of "Harbin IT-First Condor Cellular Drug Research and Development Joint Laboratory" was held in Harbin Institute of Technology (Weihai).
On June 30th

the public service platform of cell quality testing of Songshan Lake (First Condor) Regional Cell Preparation Center has passed the measurement and examination of China Research Institute of Food and Drug Control, and the evaluation conclusion is "satisfactory".
On July 17th

the opening ceremony of Zalijan Biotechnology, a subsidiary of The First Condor Group, was successfully held.
On July 29th

Zhang Bin, member of the Standing Committee of Kunming Municipal Committee and executive Vice Mayor of Kunming, visited the headquarters of The First Condor Group.
On September 8th

the kick-off meeting of IIT clinical trial of First Condor Life XKDCT007 cell injection was successfully held.
On September 10th

the 2021 Shenzhen International Cell Therapy and Anti-Aging Conference and Exhibition, exclusively named by First Condor, was held.
On October 14th

the official website of Dongguan Daily--Dongguan Time.com published "Dongguan Enterprises won the Excellent Enterprise "Award in the National Biomedical Competition of the 10th China Innovation and Entrepreneurship Competition" reporting on First Condor Biotechnology.
On December 26th

the project "Development of CAR-T drug targeting solid tumors" by First Condor Life won the "Excellence Award" of the 10th Golden Doctor Award Global Finals.

2020

On February 3rd

First Condor Biotechnology was selected into the list of newl Coronavirus prevention and controlprojects in Guangdong Province.
On March 9th

Shenzhen First Condor Life Science Co., Ltd. was registered and established.
On May 15th

won the second prize of the 2019 "Win in Dongguan" Science and Technology Innovation and Entrepreneurship Competition in the Life Science and Biotechnology Industry Finalsn.
On June 23rd

was included in the list of technology-based small and medium-sized enterprises in Guangdong Province.
On August 3rd

“China Reform News” published the article "Ingenuity and creative research, deep cultivation in the health industry", focusing on First Condor Biotechnology.
On August 10th

“Dongguan Daily” published the article "Dongguan Enterprises Develop cell therapy---driven by technology R&D, First Condor Biology will be deeply involved CAR-T treatment of solid tumor project", focusing on First Condor Biotechnology.
On September 12th

won the excellence award of the 9th China Innovation and Entrepreneurship Competition (Guangdong Division) and the 8th "Pearl River Angel Cup" Science and Technology Innovation and Entrepreneurship Competition Finals.
On December 1st

passed the identification of "National High-tech Enterprise".
On December 15th

won the second prize of the Women's Special Final of the 2020 Songshan Lake Innovation and Entrepreneurship Competition.
On December 17th

won the first prize of the final of the 2020 IT Global Alumni Innovation and Entrepreneurship Competition.
On December 30th

won the third prize of the finals of the 2020 Songshan Lake Innovation and Entrepreneurship Competition final.

2019

In January

Guangdong First Condor Biotechnology Co., Ltd. was registered and officially entered the field of cell therapy.
In February

CEO Mr.Xie Haitao was appointed as the vice president of Guangdong Shandong Chamber of Commerce Shenzhen Branch, Shenzhen Qi-Lu General Chamber of Commerce and the Executive President of the Medical Chamber of Commerce.
On July 17th

the opening ceremony of First Condor Biological R&D Center was successfully held. Academician Zhong Shizhen, a senior academician of the Chinese Academy of Engineering, attended the opening ceremony and served as the honorary chairman of the first Scientific Advisory Committee.
On September 8-9th

CEO Mr.Xie Haitao was invited to attend the 16th Chinese Scientists Forum and deliver a report.
On November 8th

CEO Mr.Xie Haitao appeared on the cover of the “Chinese Celebrities and Masters” magazine.
On November 12th

It was accepted as a member of China Pharmaceutical Biotechnology Association

2018

In December 2018

the first phase of the laboratory was completed.